Maeve A OReilly
Overview
Explore the profile of Maeve A OReilly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dulobdas V, Kirkwood A, Serpenti F, Gautama B, Panopoulou A, Mathew A, et al.
Blood Cancer J
. 2025 Mar;
15(1):30.
PMID: 40032870
CAR T-cell manufacturing failure (MF) is a situation where the manufacturing process fails to yield a product or results in one which is out-of-specification (OOS). We conducted a multicentre retrospective...
2.
OReilly M, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al.
Hemasphere
. 2024 Jun;
8(6):e87.
PMID: 38873532
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19 CAR T-cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA-2, brexu-cel demonstrated impressive responses in patients failing ≥2 lines, including...
3.
Oporto Espuelas M, Burridge S, Kirkwood A, Bonney D, Watts K, Shenton G, et al.
Blood Cancer J
. 2024 Apr;
14(1):66.
PMID: 38622139
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study,...
4.
OReilly M, Neill L, Collin S, Stone N, Springell D, Mensah J, et al.
Hemasphere
. 2024 Mar;
8(1):e29.
PMID: 38434533
Infection has emerged as the chief cause of non-relapse mortality (NRM) post CD19-targeting chimeric antigen receptor T-cell therapy (CAR-T) therapy. Even though up to 50% of patients may remain infection-free,...
5.
Roddie C, Lekakis L, Marzolini M, Ramakrishnan A, Zhang Y, Hu Y, et al.
Blood
. 2023 Feb;
141(20):2470-2482.
PMID: 36821767
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1...
6.
OReilly M, Malhi A, Cheok K, Ings S, Balsa C, Keane H, et al.
Cytotherapy
. 2022 Dec;
25(3):323-329.
PMID: 36513573
Background Aims: The most widely accepted starting materials for chimeric antigen receptor T-cell manufacture are autologous CD3+ T cells obtained via the process of leukapheresis, also known as T-cell harvest....
7.
OReilly M, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, et al.
Br J Haematol
. 2022 Jul;
199(1):40-44.
PMID: 35894253
No abstract available.
8.
Roddie C, Dias J, OReilly M, Abbasian M, Cadinanos-Garai A, Vispute K, et al.
J Clin Oncol
. 2021 Aug;
39(30):3352-3363.
PMID: 34464155
Purpose: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z)...
9.
OReilly M, Govender D, Kirkwood A, Vora A, Samarasinghe S, Khwaja A, et al.
Br J Haematol
. 2019 Feb;
186(2):327-329.
PMID: 30768682
No abstract available.
10.
OReilly M, Millar S, Buckley C, Harrington J, Perry I, Cahill M
Am J Hematol
. 2015 Jun;
90(9):E196-7.
PMID: 26096846
No abstract available.